Elon Musk and RFK Jr. Clash Over Weight-Loss Drug Policies

The debate over GLP-1 drugs like Ozempic intensifies as Musk advocates for affordability while RFK Jr. emphasizes lifestyle changes.

Elon Musk, co-leader of the incoming Department of Government Efficiency, supports making GLP-1 weight-loss drugs affordable, calling it the most impactful way to improve American health.
Robert F. Kennedy Jr., President-elect Trump’s nominee for Health and Human Services Secretary, argues that promoting healthy eating and exercise should take precedence over drug solutions.
Whoopi Goldberg and co-hosts of 'The View' sided with Musk, criticizing Kennedy’s stance on diet-focused solutions as potentially shaming individuals with obesity.
The Biden administration had proposed expanding Medicare and Medicaid coverage for GLP-1 drugs, but the decision now lies with the incoming Trump administration, which has sent mixed signals on the issue.
GLP-1 drugs, including Ozempic and Wegovy, are highly effective for weight loss but remain expensive, with Musk and others calling for price reductions to match international markets.